Literature DB >> 27329210

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience.

B Rossi1, P Blanche1, V Roussel-Robert2, A Berezné1, S Combe2, P Coppo3, L Guillevin1, C Le Jeunne1, L Mouthon1, N Ounnoughene2, N Stieltjes2, M Groh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27329210     DOI： 10.1111/hae.12973

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  2 in total

1.  Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.

Authors:  Sumita Ratnasingam; Patricia A Walker; Huy Tran; Zane S Kaplan; James D McFadyen; Huyen Tran; Tse-Chieh Teh; Shaun Fleming; John V Catalano; Sanjeev D Chunilal; Anna Johnston; Stephen S Opat; Jake Shortt
Journal:  Blood Adv       Date:  2016-11-22

Review 2.  Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature.

Authors:  Imad Ghozlani; Aziza Mounach; Mirieme Ghazi; Anass Kherrab; Radouane Niamane
Journal:  Am J Case Rep       Date:  2018-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.